Purchase this article with an account.
Hideo Nakanishi, Akitaka Tsujikawa, Kenji Yamashiro, Akio Oishi, Sotaro Ooto, Hiroshi Tamura, Nagahisa Yoshimura; Prognostic Factor for Visual Outcomes Two-Years after Intravitreal ranibizumab for Myopic Choroidal Neovascularization. Invest. Ophthalmol. Vis. Sci. 2014;55(13):4944.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the visual outcome 24 months after intravitreal ranibizumab (IVR) for myopic choroidal neovascularization (mCNV), and to determine the effect of pre-treatment ocular factors on the visual outcome.
Twenty-three eyes of 23 patients (4 men and 16 women, the mean age [± standard deviation] was 65.6 ± 11.1 years) with treatment-naiive mCNV were treated with IVR followed by pro re nata (PRN) therapy. The efficacy of IVR was evaluated by the best-corrected visual acuity (BCVA) at 3, 6, 12, and 24 months after the initial treatment. Stepwise multiple linear regression analyses were performed to evaluate the influence of pre-treatment factors (age, duration of symptom, axial length, pre-treatment BCVA in logarithm of the minimum angle of resolution [logMAR] units, pre-treatment CNV size, and pre-treatment CNV location as subfoveal or juxtafoveal) on the BCVA and the improvement of the BCVA at 24 months.
The mean pre-IVR BCVA was 0.59 ± 0.30 logMAR units and it improved to 0.36 ± 0.35 logMAR units after three month (P <0.005). The improvement was maintained at 24 months (0.35 ± 0.40 logMAR units, P <0.005). Of the 23 eyes, nine eyes (39.1 %) had IVR only once; mean number of injections was 2.2 ± 1.3 times at 24 months after the initial treatment. Stepwise regression analysis showed that the pre-IVR BCVA (standardized β =0.51, P<0.005) and CNV size (standardized β =0.46, P<0.005) significantly affected the BCVA after 24 months. The pre-IVR CNV location (juxtafoveal) was the only factor that affected the visual acuity improvement after 24 months (standardized β =0.54, P<0.05).
IVR with PRN therapy for mCNV led to a sustained visual improvement for 24 months after initial treatment. Good pre-IVR BCVA and smaller CNV size were significant prognostic factors that predicts better visual acuity. Patients with juxtafoveal CNV had better visual recovery than those with subfoveal CNV.
This PDF is available to Subscribers Only